Phase 2CompletedINTERVENTIONAL
A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction
ClinicalTrials.gov · NCT02814097 · Registry updated: 2017-09-07
- Condition / research focus
- Chronic Heart Failure
- Sponsor
- Stealth BioTherapeutics Inc.
- Countries with listed sites
- Germany · Serbia
- Registry dates and results
- Start: 2016-09-02. Completion: 2017-06-02 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- elamipretide (drug) — also listed as: MTP-131, Bendavia
- Placebo (drug)
Where the study takes place — 9 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum
Berlin, Germany
Site recruitment: Not reported - German Heart Center
Berlin, Germany
Site recruitment: Not reported - Clinical Centre of Serbia, Clinic for Cardiology
Belgrade, Serbia
Site recruitment: Not reported - Clinical Hospital Center "Dr Dragiša Mišović-Dedinje", Department of Cardiology
Belgrade, Serbia
Site recruitment: Not reported - Clinical Hospital Center "Zvezdara", Department of Cardiology
Belgrade, Serbia
Site recruitment: Not reported - Clinical Hospital Center "Bežanijska Kosa", Department of Cardiology
Belgrade, Serbia
Site recruitment: Not reported - Clinical Hospital Center "Zemun", Department of Cardiology
Belgrade, Serbia
Site recruitment: Not reported - Institute for Cardiovascular Diseases Vojvodina, Clinic for Cardiology
Kamenitz, Serbia
Site recruitment: Not reported - Clinical Center Niš, Clinic for Cardiology
Niš, Serbia
Site recruitment: Not reported